Brief: Invivyd Announces Positive Full Phase 1/2 Clinical Data For Vyd2311
26/06/2025 12:01
June 26 (Reuters) - Invivyd Inc IVVD.O: INVIVYD ANNOUNCES POSITIVE FULL PHASE 1/2 CLINICAL DATA FOR VYD2311, A NEXT GENERATION COVID-19 MONOCLONAL ANTIBODY FOR POTENTIAL USE AS A NON-VACCINE PREVENTATIVE AND FOR TREATMENT OF ACTIVE INFECTION INVIVYD INC - VYD2311 SHOWS ATTRACTIVE SAFETY PROFILE ACROSS ALL DOSING COHORTS INVIVYD INC - TYPE C MEETING WITH FDA SCHEDULED FOR EARLY Q3 Source text: ID:nGNX8R7BBD Further company coverage: IVVD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview